Blog December 2, 2021
With the seismic shift we’re witnessing with Environmental, Social and Governance (ESG) developments, we know stakeholders are expecting more—encouraging ambitious commitments and exploring the ways to leverage resources, even green financing.
Blog December 2, 2021
Everyone feels differently about weight, weight gain, and health—some welcome interventions while others bristle at them. It’s our job to meet people where they are with what matters most to them.
Blog November 19, 2021
Over the last 18 months, an evolution in diabetes management has accelerated, and for good reason. There are three potential solutions for pharma, device, or DTx marketers to consider based on trends we’ll see in the year ahead.
Blog November 19, 2021
There’s a bigger problem than diabetes—prediabetes, affecting 34.5% of the US adult population (as compared to 10.5% with diabetes), and there’s a likely and significant opportunity for tech to tackle this, with benefits to people and to society.
Blog November 12, 2021
This month policies aimed at lowering drug prices are back on the table. It’s noticeably less ambitious than earlier Democratic proposals, but still represents a historic shift in how drug pricing is approached in the United States.
Blog November 12, 2021
Diabetes is an epidemic with a devastating physical, emotional and financial toll on those it impacts. And with a now greater need and use for new tech, we explore two key trends shaping a new diabetes landscape that places digital therapeutics at its core.
Blog November 3, 2021
Many HCPs—neurologists included—need mechanisms to bridge the gap from emotional alignment with their patients to action by delivering on patient unmet needs. Aligning pharma understanding with HCP intention is a critical first step.
Blog November 2, 2021
With more than 10,000 health and wellness apps available today, we explored the ways in which digital innovation has transformed the expectations consumers have for how brands solve for mental health challenges.
Blog October 8, 2021
Looking at what the conventionally siloed functions of Brand and Innovation stand to gain from collaborating.
Blog September 30, 2021
A look at two key health literacy best practices, from a behavioral science perspective.
Blog September 16, 2021
An update on the latest developments in Washington critical to Pharma leaders.
Blog September 16, 2021
An exploration of how different sub-sectors of Pharma ought to be approaching innovation in consumer health.
Blog September 9, 2021
Our health systems and treatment options have, over the years, exponentially increased the levels of complexity in navigating health decisions.
Blog September 2, 2021
Why Pharma Companies Should Focus their Innovation Efforts on Health Categories Beyond Medication
Blog August 26, 2021
The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.
Blog August 26, 2021
With the devastating rise of the Delta variant, we’re now seeing news reminiscent of the early days of the pandemic: Hospitals are reaching capacity, with 1 in 5 ICUs having at least 95% of their beds filled.
Blog August 19, 2021
In its most basic definition, Customer Experience (CX) strategy shapes and defines the way a brand interacts with its customers throughout their purchasing journey.
Blog August 12, 2021
The COVID-19 guidelines released by the Centers for Disease Control (CDC) in May, proclaiming that vaccinated people no longer needed to wear masks indoors, spurred widespread joy, seeming to herald the beginning of the end of times unprecedented.
Blog August 12, 2021
This month, we’ve seen a flurry of activity that confirms Washington will be focused on drug pricing this summer, and it’s coming from all directions: Congress, the Biden Administration, and Courts.
Blog August 12, 2021
Science is at the foundation of everything we do. Published peer-reviewed data gives us the citeable sources we need for future projects. But what is the value of the best data if it is not communicated well or if no one “hears” it?
Blog August 5, 2021
Within a few days of the Aduhelm approval, the conversation quickly shifted from the first treatment for Alzheimer’s disease to the exorbitant cost ($56,000 annually) and whether the budgetary impact on society of the drug’s broad label is worth the therapeutic outcomes.
Blog August 5, 2021
More than 20 years ago, Gleevec ushered in a therapeutic revolution in oncology based on a relatively simple premise: If cancer cells are “addicted” to oncogenic mutations, targeting the troublesome protein might provide long-lasting disease control.
Blog July 29, 2021
There’s a lot to be said about how our world has changed over the years. But recently, what’s arguably changed the most is the speed at which companies from across all sectors are adopting and incorporating new digital approaches to their businesses.
Blog July 29, 2021
We’ve been delving into each of the four core human truths that shape our behavioral approach to brand strategy, in this month’s four-part series on the Motivational Edge (ME).
Blog July 23, 2021
Cannes Lions 2021: The Behavioral Science Behind Choice Winners
Blog July 23, 2021
Our proprietary framework for building winning brands, the Motivational Edge (ME), works because it connects with people in both their internal and external worlds.
Blog July 15, 2021
Brand Planning with the Motivational Edge, Part II: Validation
Blog July 14, 2021
The Case for a Strong Corporate or Master Brand: the Next Step in the Evolution of the Pharma Industry
Blog July 9, 2021
It’s natural to think of healthcare as a uniquely objective realm of marketing, with a product’s value always rooted in its efficacy and safety. Needless to say, scientific story is an essential part of any product’s positioning.
Blog July 9, 2021
It’s that time of year again. The time of year when our clients, and thus, our teams embark on the odyssey that is Brand Planning. That’s right, it’s an odyssey, but often not the kind that evokes a thrill or feelings of joy.
Already have a RSS feed reader?
